NGS Testing from
Liquid Biopsy

for Cancer Genomic Profiling

NGS Testing from
Liquid Biopsy

for Cancer Genomic Profiling

NGS Testing from
Liquid Biopsy

for Cancer Genomic Profiling

Understanding NGS testing from
Liquid Biopsy

Liquid biopsy, utilizing circulating tumor DNA (ctDNA) from peripheral blood, provides a minimally invasive approach to comprehensive genomic profiling. This technique delivers real-time insights into tumor biology, tracking both the current molecular status and therapeutic response over time. Particularly beneficial in cases where tissue biopsy is impractical, liquid biopsy enables ongoing monitoring of treatment efficacy and helps in identifying emerging resistance mechanisms—essential for adapting therapy in precision oncology.

Liquid Biopsy Tests Portfolio

TARGT First Liquid

TARGT First Liquid is a focused pan-cancer liquid biopsy test that utilizes end to end sequencing of 72 frequently mutated genes associated with cancer. It offers high sensitivity and specificity for detecting somatic alterations, providing an effective minimally invasive solution.
TARGT First Liquid delivers comprehensive evidence for targeted therapies and prognostication by sequencing critically important genomic biomarkers. It ensures compatibility with NCCN and FDA-approved therapies, covering actionable mutations in solid tumors to support precise and optimized treatment planning.

TARGT Indiegene Liquid

TARGT Indiegene is the most comprehensive minimally invasive liquid biopsy test, analyzing 1,212 genes linked to cancer treatment and prognosis. This assay offers ctDNA-based genomic profiling to detect alterations such as SNVs/InDels, CNAs, gene fusions/splice variants, and MSI.
The test focuses on therapeutically relevant gene fusions commonly found in both common and rare cancers, including ALK, ROS1, RET, MET Exon 14 skipping, NTRK1/2/3, FGFR2/3, and NRG1/2, providing critical insights for personalized cancer care. It also evaluates MSI, which is crucial for immunotherapy response, monitoring treatment efficacy, and detecting early resistance, enabling more informed clinical decisions.

Advantages of Liquid Biopsy Testing

Minimally-Invasive and Safer for Patients

Liquid biopsy uses a simple blood sample to analyze circulating tumor DNA (ctDNA), making it a minimally invasive alternative to traditional tissue biopsies. This approach is safer, less painful, and can be repeated easily, reducing patient discomfort.

Early Detection of Resistance Mutations

By detecting emerging mutations in ctDNA, liquid biopsy can identify signs of therapeutic resistance before they become clinically apparent. This proactive approach allows for timely adjustments in treatment, improving patient outcomes.

Real-Time Monitoring of Treatment Efficacy

Liquid biopsy enables continuous tracking of tumor DNA in the bloodstream, allowing oncologists to monitor how well a treatment is working over time. This real-time insight helps in assessing treatment response and adapting strategies promptly.

Broader Accessibility for Challenging Cases

Liquid biopsy is especially beneficial for patients where traditional tissue biopsies are challenging or impractical, such as those with tumors in hard-to-access locations. This makes it a valuable tool for a wider range of cancer patients, ensuring they still receive comprehensive genomic profiling.

Get Started with Liquid Biopsy Testing

Discover the benefits of non-invasive liquid biopsy testing. Contact us for a consultation.

Consult Now
loader